Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAZMINE: Zanidatamab + Tucatinib + Chemotherapy in HER2-Positive Advanced Breast Cancer
NCT07494448Phase 2Not yet recruiting
- Sponsor
- MEDSIR
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of zanidatamab in breast cancer (2 arms), sponsored by MEDSIR. Primary endpoint: Recommended Phase II Dose at 24 days. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
zanidatamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07494448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07494448.